FRM
HARP

Fox Run Management’s Harpoon Therapeutics, Inc. Common Stock HARP Stock Holding History

Fox Run Management’s Portfolio HARP Stock Details HARP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,039
Closed -$82K – 756
2021
Q3 		$82K Buy
+1,039
New +$104K 0.05% 436

Other funds holding HARP

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Fox Run Management's HARP Position: Q4 2021 in Review

Fox Run Management sold out of Harpoon Therapeutics, Inc. Common Stock (HARP) in Q4 2021, closing a stake of 1,039 shares — an estimated $82K sold.

Fox Run Management first reported a position in HARP in Q3 2021 and held it in 1 quarter. The position peaked at $82K in Q3 2021. 84 funds tracked by Wall St. Rank hold HARP as of Q4 2021.

  • Fox Run Management reported no remaining Harpoon Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Fox Run Management sold 1,039 Harpoon Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $82K.
  • Fox Run Management first reported a position in Harpoon Therapeutics, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Fox Run Management's Harpoon Therapeutics, Inc. Common Stock position peaked at $82K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Harpoon Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Fox Run Management's 13F filing for Q4 2021, filed 9 Feb 2022.